The biggest surge in new ETFs during the past 12 months has switched from ESG/Other thematic to actively managed ETFs. The preponderance of these new offerings and filings have come from major mutual fund houses and investment banks. Three ETFs are compared below regarding this topic. I’ve recently written an article that explains the many … Read more
About a month ago, this blog profiled the defensive qualities of the three largest ETFs representing the US Consumer Staples Sector. One of our readers asked a logical question. How did DEF, the Invesco Defensive Equity ETF, stack up against the sector ETFs? After all, its objective of its rules-based methodology is to select companies … Read more
The ETF reports on ValuEngine for funds that follow market benchmarks provide a side benefit in writing market analyses. They allow me to discuss the implicit forecast for 1-, 3-, 6- and 12-month forecasts our models are making for each benchmark’s ETF portfolio. This is because the ratings and projections combine bottom-up constituent analysis with … Read more
For each blog article, I scan through relevant groups of ETFs that relate to possible investment strategies. Three ETFs from iShares by BlackRock stood out to me this week: IEO, IEZ, IYE. All have ValuEngine’s strongest rating of 5 checks and all have fared very well in price performance during the past 6 months since … Read more
This week’s featured US equity ETFs, all focused on the US Consumer Staples Sector, are projected to outperform the market going forward. The similarities with last week’s blog end there. These all get a more modest 4 (buy) recommendation. Risk versus safety differentiate the last blog from this one. My last blog entry profiled ETF … Read more
The events of the past twelve months focused a lot of attention on amazing and life-altering developments made possible by the global biotech industry. Although the major names we heard were Pfizer, AstraZeneca, Johnson & Johnson and Moderna, only the last was where the original research and patents that produced the CoVid-19 vaccines were developed. … Read more
The market has been in a value phase the past 6 months which has been well documented by others. The regime change was heartily welcomed by almost all managers of value funds, both active and passive. This is because the previous 13 years have been relentlessly difficult for value managers in terms of relative performance … Read more
Lately, ValuEngine has seen ticker GVIP (Goldman Sachs Hedge Industry VIP ETF) on several ETF strategists’ buy lists. The fund’s strategy is intended to take advantage of the highest conviction holdings of “VIP Hedge Fund Managers.” Specifically, GVIP seeks to track the GS Hedge Fund VIP Index, which is constructed in accordance with a rules-based … Read more
By Herb Blank If you are an investor with less than $1 billion to invest and a holding horizon of more than 3 months, do NOT buy SPY to access exposure to the S&P 500. This is true even though SPY has the most assets under management and the highest average trading volume by far. The simple … Read more
By Herbert Blank Actively managed ETFs have evolved very differently from index-driven ETFs. Most of the assets have been accumulated in actively managed fixed income ETFs while the vast preponderance of Assets Under Management in Equity ETFs are index driven. Although there are many legacy reasons for this, the fact is that the efficiencies of … Read more